Company registration number 15449695 (England and Wales)
MEDICO PHARMACEUTICALS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025
PAGES FOR FILING WITH REGISTRAR
MEDICO PHARMACEUTICALS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
MEDICO PHARMACEUTICALS LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2025
31 January 2025
- 1 -
2025
Notes
£
£
Current assets
Debtors
3
1,355
Cash at bank and in hand
100
1,455
Creditors: amounts falling due within one year
4
(11,408)
Net current liabilities
(9,953)
Capital and reserves
Called up share capital
100
Profit and loss reserves
(10,053)
Total equity
(9,953)

For the financial Period ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the Period in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 23 October 2025
Mr R Jolly
Director
Company registration number 15449695 (England and Wales)
MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025
- 2 -
1
Accounting policies
Company information

Medico Pharmaceuticals Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 5, Winsor And Newton Building, Whitefriars Avenue, Harrow, England, HA3 5RN.

1.1
Reporting period

These are the first set of financial statements prepared by the company after the incorporation. Therefore, there are no comparatives included and the financial statements are prepared for the period of one year and three days.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.3
Going concern

A true t the time of approving the financial statements, t he director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount re ceived is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 JANUARY 2025
1
Accounting policies
(Continued)
- 3 -
1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 JANUARY 2025
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the Period was:

2025
Number
Total
0
3
Debtors
2025
Amounts falling due within one year:
£
Trade debtors
1,200
Other debtors
155
1,355
4
Creditors: amounts falling due within one year
2025
£
Trade creditors
5,100
Other creditors
6,308
11,408
5
Related party transactions
Transactions with related parties

During the Period the company entered into the following transactions with related parties:

Management charges
2025
£
Entities with control, joint control or significant influence over the company
1,000
2025
Amounts due to related parties
£
6,308
MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 JANUARY 2025
5
Related party transactions
(Continued)
- 5 -

Included in other creditors are loans owed to related companies with common directors and shareholders totalling £6,308. The loans are unsecured, interest free and repayable on demand.

2025-01-31 2024-01-29 false false false 23 October 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Mr R Jolly 15449695 2024-01-29 2025-01-31 15449695 2025-01-31 15449695 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 15449695 core:ShareCapital 2025-01-31 15449695 core:RetainedEarningsAccumulatedLosses 2025-01-31 15449695 bus:Director1 2024-01-29 2025-01-31 15449695 core:CurrentFinancialInstruments 2025-01-31 15449695 core:WithinOneYear 2025-01-31 15449695 bus:PrivateLimitedCompanyLtd 2024-01-29 2025-01-31 15449695 bus:SmallCompaniesRegimeForAccounts 2024-01-29 2025-01-31 15449695 bus:FRS102 2024-01-29 2025-01-31 15449695 bus:AuditExemptWithAccountantsReport 2024-01-29 2025-01-31 15449695 bus:FullAccounts 2024-01-29 2025-01-31 xbrli:pure xbrli:shares iso4217:GBP